have undertaken a seminal study that demonstrates improvement of physical function in elderly individuals with evidence of frailty who were treated with an oral growth hormone secretagogue.
Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$3.4B global GH market from injectable to oral therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results